Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial
Status:
Withdrawn
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Novel coronavirus SARS(Severe Acute Respiratory Syndrome)-CoV-2 was first identified during
the outbreak in Wuhan, China in December 2019 with the now resulting pandemic. Aggressive
supportive care is the mainstay of treatment currently and rescue with lung protective
mechanical ventilation is essential for survival in patients with severe acute respiratory
distress syndrome. Despite supportive care, mortality is significant in hospitalized patients
in the U.S., especially among patients > 65 years of age. Pharmacologic treatments to
decrease disease severity are urgently needed. Hydroxychloroquine is currently widely used
for treatment of autoimmune disease including systemic lupus erythematosus and rheumatoid
arthritis, and it has been used to prevent and treat malaria. In vitro and in vivo antiviral
activity towards SARS-CoV-2 has been reported. Since hydroxychloroquine has been used for
decades its properties as a drug are well known. The investigators propose a pragmatic trial
of hydroxychloroquine in moderately ill hospitalized adults with SARS-CoV-2 pneumonia with
the hypothesis that hydroxychloroquine reduces severity of acute lung injury caused by
SARS-CoV-2 infection.